Rabbit Recombinant Monoclonal FOXO1A antibody. Suitable for IHC-P, WB and reacts with Human, Mouse, Rat samples. Cited in 29 publications.
IgG
Rabbit
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
IHC-P | IP | Flow Cyt | WB | ICC/IF | |
---|---|---|---|---|---|
Human | Tested | Not recommended | Not recommended | Tested | Not recommended |
Mouse | Expected | Not recommended | Not recommended | Tested | Not recommended |
Rat | Expected | Not recommended | Not recommended | Tested | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/250 - 1/500 | Notes The mouse and rat recommendation is based on the WB results. We do not guarantee IHC-P for mouse and rat. Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/1000 - 1/10000 | Notes - |
Species Rat | Dilution info 1/1000 - 1/10000 | Notes - |
Species Human | Dilution info 1/1000 - 1/10000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Select an associated product type
Transcription factor that is the main target of insulin signaling and regulates metabolic homeostasis in response to oxidative stress (PubMed:10358076, PubMed:12228231, PubMed:15220471, PubMed:15890677, PubMed:18356527, PubMed:19221179, PubMed:20543840, PubMed:21245099). Binds to the insulin response element (IRE) with consensus sequence 5'-TT[G/A]TTTTG-3' and the related Daf-16 family binding element (DBE) with consensus sequence 5'-TT[G/A]TTTAC-3' (PubMed:10358076). Activity suppressed by insulin (PubMed:10358076). Main regulator of redox balance and osteoblast numbers and controls bone mass (By similarity). Orchestrates the endocrine function of the skeleton in regulating glucose metabolism (By similarity). Also acts as a key regulator of chondrogenic commitment of skeletal progenitor cells in response to lipid availability: when lipids levels are low, translocates to the nucleus and promotes expression of SOX9, which induces chondrogenic commitment and suppresses fatty acid oxidation (By similarity). Acts synergistically with ATF4 to suppress osteocalcin/BGLAP activity, increasing glucose levels and triggering glucose intolerance and insulin insensitivity (By similarity). Also suppresses the transcriptional activity of RUNX2, an upstream activator of osteocalcin/BGLAP (By similarity). In hepatocytes, promotes gluconeogenesis by acting together with PPARGC1A and CEBPA to activate the expression of genes such as IGFBP1, G6PC1 and PCK1 (By similarity). Important regulator of cell death acting downstream of CDK1, PKB/AKT1 and STK4/MST1 (PubMed:18356527, PubMed:19221179). Promotes neural cell death (PubMed:18356527). Mediates insulin action on adipose tissue (By similarity). Regulates the expression of adipogenic genes such as PPARG during preadipocyte differentiation and, adipocyte size and adipose tissue-specific gene expression in response to excessive calorie intake (By similarity). Regulates the transcriptional activity of GADD45A and repair of nitric oxide-damaged DNA in beta-cells (By similarity). Required for the autophagic cell death induction in response to starvation or oxidative stress in a transcription-independent manner (PubMed:20543840). Mediates the function of MLIP in cardiomyocytes hypertrophy and cardiac remodeling (By similarity). Regulates endothelial cell (EC) viability and apoptosis in a PPIA/CYPA-dependent manner via transcription of CCL2 and BCL2L11 which are involved in EC chemotaxis and apoptosis (PubMed:31063815).
Forkhead box protein O1, Forkhead box protein O1A, Forkhead in rhabdomyosarcoma, FOXO1A, FOXO1, FKHR
Rabbit Recombinant Monoclonal FOXO1A antibody. Suitable for IHC-P, WB and reacts with Human, Mouse, Rat samples. Cited in 29 publications.
IgG
Rabbit
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
EPR12020
Affinity purification Protein A
The mouse and rat recommendation is based on the WB results. We do not guarantee IHC-P for mouse and rat.
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This supplementary information is collated from multiple sources and compiled automatically.
FOXO1A also known as forkhead box O1 FOXO1 or FOXO1 transcription factor is a protein with a molecular weight of approximately 70 kDa. It is an important transcription factor in the FOXO family responsible for regulating gene expression in response to environmental and physiological stimuli. FOXO1A predominantly localizes in the nucleus but can translocate to the cytoplasm under certain conditions. Expression of FOXO1A occurs in various tissues including liver adipose tissue and pancreatic islets indicating its broad functional roles in different organs.
FOXO1A acts as a regulator of metabolic pathways apoptosis and cell cycle regulation. Its role in glucose metabolism stands out as a critical function where it influences insulin signaling and glucose homeostasis. FOXO1A can also form complexes with other transcription factors like PPARγ enhancing its regulatory capacity. Interactions within these complexes dictate the transcriptional outcomes influencing cellular responses to stress and growth signals.
The FOXO1 transcription factor plays a critical role in the insulin signaling and PI3K-Akt pathway. These pathways are essential for maintaining energy balance and cellular survival. FOXO1A interacts with proteins like Akt which phosphorylates FOXO1A resulting in its cytoplasmic sequestration and subsequent inactivation. This regulation is vital for insulin-mediated glucose uptake and overall metabolic homeostasis preserving cellular functions under fluctuating nutrient conditions.
Aberrant FOXO1A activity is associated with type 2 diabetes and certain cancers. Dysregulation leads to impaired insulin signaling and glucose metabolism contributing to insulin resistance and hyperglycemia in diabetes. In cancer altered FOXO1A expression affects apoptosis and cell proliferation influencing tumor progression and survival. Associations with proteins such as Akt and PPARγ in these conditions further exemplify its network in disease mechanisms highlighting its potential as a therapeutic target.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Lane 1: Wild-type HAP1 whole cell lysate (20 μg)
Lane 2: FOXO1A knockout HAP1 whole cell lysate (20 μg)
Lanes 1 - 2: Merged signal (red and green). Green - ab179450 observed at 69 kDa. Red - loading control, Anti-GAPDH antibody [mAbcam 9484] - Loading Control ab9484, observed at 37 kDa.
Unpurified ab179450 was shown to specifically react with FOXO1 (FOXO1A) in wild-type HAP1 cells along with additional cross reactive bands. No bands were observed when FOXO1 (FOXO1A) knockout cells were examined. Wild-type and FOXO1 (FOXO1A) knockout samples were subjected to SDS-PAGE. ab179450 and Anti-GAPDH antibody [mAbcam 9484] - Loading Control ab9484 (Mouse anti GAPDH loading control) were incubated overnight at 4°C at 1/1000 dilution and 1/10,000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-FOXO1A antibody [EPR12020] (ab179450)
Predicted band size: 69 kDa
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human tonsil tissue sections labeling FOXO1A with purified ab179450 at 1/250 dilution (4.73 µg/ml). Perform heat mediated antigen retrieval using Antigen Retrieval Buffer (100X Tris-EDTA Buffer, pH 9.0) ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control: PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
The molecular weight observed is consistent with what has been described in PMID: 20406953
All lanes: Western blot - Anti-FOXO1A antibody [EPR12020] (ab179450) at 1/1000 dilution
Lane 1: HEK-293 (Human embryonic kidney epithelial cell) whole cell lysates at 20 µg
Lane 2: Mouse heart lysates at 20 µg
Lane 3: Rat heart lysates at 20 µg
Lane 4: Rat spleen lysates at 20 µg
All lanes: Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 69 kDa
Observed band size: 70-75 kDa
All lanes: Western blot - Anti-FOXO1A antibody [EPR12020] (ab179450) at 1/1000 dilution
Lane 1: HepG2 cell lysate at 10 µg
Lane 2: HeLa cell lysate at 10 µg
Lane 3: 293T cell lysate at 10 µg
Predicted band size: 69 kDa
Immunohistochemical analysis of paraffin-embedded Human DLBCL tissue labeling FOXO1A with unpurified ab179450 at 1/250 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Immunohistochemical analysis of paraffin-embedded Human tonsil tissue labeling FOXO1A with unpurified ab179450 at 1/250 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Blocking and diluting buffer and concentration: 5% NFDM/TBST
In Western blot, anti-FOXO1A antibody (ab179450) staining at 1/1000 dilution.
In Western blot, anti-His antibody (Anti-6X His tag® antibody [EPR20547] - ChIP Grade ab213204) staining at 1/5000 dilution.
Exposure time: 3 minutes.
All lanes: Western blot - Anti-FOXO1A (pT24)+FOXO3A (pT32)+FOXO4 (pT28)+FOXO6 (pT26) antibody [EPR28359-78] (Anti-FOXO1A (pT24)+FOXO3A (pT32)+FOXO4 (pT28)+FOXO6 (pT26) antibody [EPR28359-78] ab312326) at 1/1000 dilution
Lane 1: Untreated 293T (human embryonic kidney epithelial cell) transfected with mouse FOXO1A (WT) expression vector containi a myc-His-tag® whole cell lysate at 20 µg
Lane 2: 293T transfected with mouse FOXO1A (WT) expression vector containi a myc-His-tag®, then treated with 100nM Calyculin A for 30min whole cell lysate at 20 µg
Lane 3: Untreated 293T transfected with mouse FOXO1A (Mutant T24A) expression vector containi a myc-His-tag® whole cell lysate at 20 µg
Lane 4: 293T transfected with mouse FOXO1A (Mutant T24A) expression vector containi a myc-His-tag®, then treated with 100nM Calyculin A for 30min whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Observed band size: 78-82 kDa
Exposure time: 3min
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com